Ulcer and gastritis

Endoscopy. 2002 Feb;34(2):104-10. doi: 10.1055/s-2002-19843.

Abstract

The literature on peptic ulcer and gastritis in 2000 again focused on the topics of Helicobacter pylori, nonsteroidal anti-inflammatory drugs (NSAIDs), and gastric cancer. New diagnostic tests for H. pylori infection have been evaluated, and rescue therapies for failed H. pylori eradication have been tested. The causal relationship between H. pylori infection and nonulcer dyspepsia, gastric cancer, gastroesophageal reflux disease, and NSAID-related ulcers remained heated topics of debate. In 2000, landmark clinical trials and meta-analyses were published addressing these issues. The role of endoscopy in managing nonulcer dyspepsia was better defined. The role of H. pylori eradication in NSAID/aspirin users was reexamined in high-risk patients. Clinical benefit was finally confirmed for specific inhibitors of cyclooxygenase-2 (COX-2). The millennium year turned out to be a very important one in the advancement of knowledge in this field.

Publication types

  • Review

MeSH terms

  • Anti-Inflammatory Agents, Non-Steroidal / therapeutic use
  • Clarithromycin / therapeutic use
  • Cyclooxygenase Inhibitors / therapeutic use
  • Drug Therapy, Combination / therapeutic use
  • Dyspepsia / diagnosis
  • Dyspepsia / microbiology
  • Dyspepsia / therapy
  • Endoscopy, Gastrointestinal
  • Gastritis* / complications
  • Gastritis* / drug therapy
  • Gastritis* / microbiology
  • Gastroesophageal Reflux / etiology
  • Helicobacter Infections / drug therapy
  • Helicobacter pylori
  • Humans
  • Peptic Ulcer* / microbiology
  • Precancerous Conditions / microbiology
  • Proton Pump Inhibitors
  • Rifabutin / therapeutic use
  • Stomach Neoplasms / microbiology

Substances

  • Anti-Inflammatory Agents, Non-Steroidal
  • Cyclooxygenase Inhibitors
  • Proton Pump Inhibitors
  • Rifabutin
  • Clarithromycin